PubMed Journals Articles About "Zydus Spies Opportunities Brazil Mexico Along With Biosimilars" RSS

08:18 EDT 1st October 2014 | BioPortfolio

Zydus Spies Opportunities Brazil Mexico Along With Biosimilars PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Zydus Spies Opportunities Brazil Mexico Along With Biosimilars articles that have been published worldwide.

More Information about "Zydus Spies Opportunities Brazil Mexico Along With Biosimilars" on BioPortfolio

We have published hundreds of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars news stories on BioPortfolio along with dozens of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Clinical Trials and PubMed Articles about Zydus Spies Opportunities Brazil Mexico Along With Biosimilars for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Companies in our database. You can also find out about relevant Zydus Spies Opportunities Brazil Mexico Along With Biosimilars Drugs and Medications on this site too.

Showing "Zydus spies opportunities Brazil Mexico along with biosimilars" PubMed Articles 1–25 of 2,500+

Extremely Relevant

Business of biosimilars - 14th annual conference (october 15-17, 2013 - Boston, massachusetts, USA).

Competition in the biological market offers a new set of opportunities and challenges within the healthcare industry. Biosimilars, like generic small-molecule drugs, can provide cost savings and increase patient access, while also promoting innovation. While large molecule manufacturers face many challenges unique to complex therapeutics, it is becoming clear that the commercialization of biosimilars shares many of the same hurdles as the generics market. The 14th Annual Business of Biosimilars Conference p...

Biosimilars: where we were and where we are.

Abstract Recent progress in biosimilars development is overviewed, with attention to the history of issues and processes leading to current regulations, and to scientific considerations, including progress on design and operational implementation issues that arise and are peculiar to biosimilars trial design and implementation.

The advent of biosimilars: challenges and risks.

Biosimilars represent a new class of medicinal products that will have significant impact on clinical use. They are identical on an amino acid sequence level to existing reference biopharmaceutical products (originals). However, they may exhibit differences on a protein level. This paper provides a brief overview of biosimilar development and describes the risk and challenges that should be considered during the admission of biosimilars into the clinic.

Prevalent Tuberculosis (TB) at HIV diagnosis in Rio de Janeiro, Brazil: The TB/HIV in Rio (THRio) Cohort.

Although Brazil has model HIV care programs, many patients continue to present late to care. We studied the frequency of tuberculosis (TB) diagnosed at HIV diagnosis in Rio de Janeiro, Brazil, in order to quantify missed opportunities for TB prevention.

Relevant

The pharmaceutical industry tussles over biosimilars: federal and state decisions will have a big impact on pharmacists.

Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.

Prevalence of pollinosis in patients with allergic asthma, rhinitis and conjunctivitis in the South of Mexico City 2007-2013.

The prevalence of pollinosis has doubled in the past two decades. Several studies suggest that up to 50% of adult residents of Mexico City can present manifestations of respiratory allergy, and pollens from trees, grasses and weeds are a common cause. To determine the prevalence of their families and antigenic cross-reactivity allows us to offer appropriate diagnoses and treatments.

Expert perspectives on biosimilar monoclonal antibodies in breast cancer.

While biosimilars of low molecular-weight biologics such as G-CSF have been available in Europe since 2006, biosimilars of monoclonal antibodies (mAbs) have only become available in the last year. Unlike G-CSF, mAbs are large and complex and often play a direct role in the survival of patients with life-threatening illnesses such as breast cancer. Several biosimilars are currently under development for the treatment of breast cancer, and the use of biosimilars in a setting that directly impacts patient surv...

Rituximab and biosimilars - equivalence and reciprocity.

Cancer is a debilitating disease affecting millions of people daily. Over the years, cancer treatment has advanced in leaps and bounds. Antibodies are important breakthrough therapeutic agents for cancer. These agents, proteins produced by B lymphocytes of the immune system in response to antigens, bind to receptors on cell surfaces so that the antigen-antibody complexes can be recognized and destroyed by phagocytes. While each B cell synthesizes only one kind of antibody, an entire population of different ...

Haplotype and nucleotide variation in the exon 3-VNTR of the DRD4 gene from indigenous and urban populations of Mexico.

To describe the population structure of the 48-bp variable number of tandem repeats (VNTR), located in exon 3 of the dopamine receptor D4 gene (DRD4), in 41 Tarahumara from northern Mexico, 20 Mixe from southern Mexico, and 169 people from Mexico City.

Phylogeographic characteristics of vesicular stomatitis New Jersey viruses circulating in Mexico from 2005 to 2011 and their relationship to epidemics in the United States.

We analyzed the phylogenetic and time-space relationships (phylodynamics) of 181 isolates of vesicular stomatitis New Jersey virus (VSNJV) causing disease in Mexico and the United States (US) from 2005 through 2012. We detail the emergence of a genetic lineage in southern Mexico causing outbreaks in central Mexico spreading into northern Mexico and eventually into the US. That emerging lineage showed higher nucleotide sequence identity (99.5%) than that observed for multiple lineages circulating concurrentl...

Putting the Value into Biosimilar Decision Making: The Judgment Value Criteria.

Uncertainties remain the key issue surrounding biosimilars, although decisions regarding their use must be made. The challenges for policymakers, doctors, patients and others seeking to navigate in the uncharted waters of biosimilars must be clarified. At the most basic level, scientific understanding of the issue remains limited and when making decisions, policymakers must consider all those affected by health policy decisions, particularly the ultimate recipients of these medicines: the patients. The bios...

Comparative Mycobacterium tuberculosis Spoligotype Distribution in Mexico.

In the present work, we studied the genetic diversity of Mycobacterium tuberculosis clinical isolates according to the gender, age, and geographic location within Mexico. We did not observe any statistically significant difference considering age and gender. We found that SIT53 is more frequent in the northern states and that SIT119 predominates in central Mexico.

Alergia México: an Ibero-American journal.

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets.

Trastuzumab in combination with chemotherapy has become a standard of care for patients with HER2+ breast cancer. The cost of therapy, however, can limit patient access to trastuzumab in areas with limited financial resources for treatment reimbursement. This study examined access to trastuzumab and identified potential barriers to its use in the United States, Mexico, Turkey, Russia and Brazil via physician survey. The study also investigated if the availability of a biosimilar to trastuzumab would improve...

Patient Perspectives on Biosimilar Insulin.

Given that a new wave of biosimilar insulins will likely enter the market in coming years, it is important to understand patient perspectives on these biosimilars. A survey (N = 3214) conducted by the market research company dQ&A, which maintains a 10 000-patient panel of people with type 1 or type 2 diabetes in roughly equal measure, investigated these perspectives. The survey asked whether patients would switch to a hypothetical less expensive biosimilar insulin that was approved by their provider. Approx...

Epidemic risk from cholera introductions into Mexico.

Stemming from the 2010 cholera outbreak in Haiti, cholera transmission in Hispaniola continues with over 40,000 cases in 2013. The presence of an ongoing cholera outbreak in the region poses substantial risks to countries throughout the Americas, particularly in areas with poor infrastructure. Since September 9, 2013 nearly 200 cholera cases have been reported in Mexico, as a result of introductions from Hispaniola or Cuba. There appear to have been multiple introductions into Mexico resulting in outbreaks ...

Review and redescription of species in the Oecetis avara group, with the description of 15 new species (Trichoptera, Leptoceridae).

The O. avara group of Oecetis is formally defined to include 4 described species, O. avara (Banks), O. disjuncta (Banks), O. elata Denning & Sykora, and O. metlacenis Bueno-Soria, and 15 new species. Oecetis marquesi Bueno-Soria, previously considered a member of the O. avara group, is treated as incertae sedis to species group, but is also redescribed and treated in the current work. New species described here (with their respective distributions) include: O. acciptrina (Costa Rica, Panama, Ecuador), O. ag...

Widowhood in Los Robles: Parent-child relations and economic survival in old age in urban Mexico.

In rural Mexico the burden of care for widowed and elderly mothers has traditionally fallen on sons; but Mexico is now more than 70% urban and, in the city, patterns of support for aging parents vary widely. In the face of steep inflation, widespread unemployment and economic stagnation, young people are increasingly hesitant to offer support, while older people feel less entitled to and more ambivalent about requesting it.

Urticaria in children attending allergy services.

There is little information on urticaria occurring in children, especially in limited resource countries.

Biosimilars: what's in a name?

A new species of Amphictene (Annelida, Pectinariidae) from the Gulf of Mexico, with a redescription of Amphictene guatemalensis (Nilsson, 1928).

The genus Amphictene is reported for the first time from Mexico. Previous records for America are restricted to Brazil (Amphictene catharinensis) (Grube, 1870), and Guatemala (Amphictene guatemalensis) (Nilsson, 1928). In this paper we describe a new species, Amphictene helenae sp. n., characterized by the presence of three pairs of tentacular cirri, while other species have only two pairs. The new species is closely similar to Amphictene catharinensis, and can be distinguished by the presence of a circular...

Biosimilars.

.

Hitting the Wall: Youth Perspectives on Boredom, Trouble, and Drug Use Dynamics in Rural New Mexico.

We examine the experience of boredom and its relationship to troublemaking and drug use among rural youth in southwestern New Mexico. We draw on qualitative research with area youth to describe what they think about drug use and how they situate it within their social circumstances. We then locate youth drug use within globalized processes affecting this setting, including a local economic environment with limited educational and employment opportunities for youth. Drug use emerges as a common social practi...

Policy Development for Environmental Licensing and Biodiversity Offsets in Latin America.

Attempts to meet biodiversity goals through application of the mitigation hierarchy have gained wide traction globally with increased development of public policy, lending standards, and corporate practices. With interest in biodiversity offsets increasing in Latin America, we seek to strengthen the basis for policy development through a review of major environmental licensing policy frameworks in Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela. Here we focused our review on an examination of...

First biosimilars trickle into US pathway.


Search BioPortfolio:
Loading
Advertisement
Advertisement

PubMed Database Quicklinks